Business Update and December 2020 Quarter Cashflow

Commentary

• Sales contracts executed: Clinical Trials sales contracts totalled $14.3 million during 2Q21. Total sales contracts executed for the calendar year to 31 December 2020 was $41.7 million

. • Trading Conditions Update: In the Clinical Trials segment, pharmaceutical company customers have continued to demonstrate a willingness to initiate new trials, notwithstanding the ongoing pandemic conditions.

• Revenue: Given the significance of the global license agreement that the Company entered into with Eisai Co. Ltd on 26 October 2020 for access to Cogstate technology, Cogstate is working with its advisers and auditors on the appropriate accounting treatment for the agreement. Audited half year revenue results will be included with the financial statements for the period ended 31 December 2020 which are scheduled to be released on 25 February 2021. This release includes details of the non-refundable cash payment which Eisai paid to the Company pursuant to the global license agreement during the quarter.

• Cash inflow: A total cash inflow of $13.95 million for the December 2020 quarter, including net operating cash inflow of $15.5 million. o Cash receipts from customers of $22.3 million for the quarter. This includes receipt of $15 million form Eisai. o Trade receivables balance increased from $5.0 million at 30 September 2020 to $5.5 million at 31 December 2020.

Mushroompanda said a few months ago "Worth a look" & I think so too